Richie Jain serves as Chief Financial Officer at Schrödinger, Inc., a pioneering computational platform company revolutionizing drug discovery and materials science through physics-based simulations. With more than 20 years of experience in finance, investment banking, and biotechnology, Jain is responsible for driving the company's financial strategy, including capital allocation, investor relations, treasury operations, and risk management. His leadership supports Schrödinger's mission to transform the discovery of novel medicines and advanced materials by ensuring robust financial health amid rapid innovation and market expansion. Prior to joining Schrödinger in 2021, Jain was CFO at Turning Point Therapeutics, where he spearheaded financial operations leading to the company's $4.1 billion acquisition by Bristol Myers Squibb in 2022. Earlier in his career, he spent over a decade at Goldman Sachs as a Managing Director in the Healthcare Investment Banking group, advising on transformative transactions such as IPOs, mergers, and financings totaling billions of dollars for biotech and pharmaceutical leaders. Jain holds an MBA from The Wharton School and a B.S. in Economics from The Wharton School at the University of Pennsylvania. Under Jain's stewardship, Schrödinger has strengthened its balance sheet and pursued strategic growth opportunities, including partnerships and platform enhancements that position the company for long-term value creation in computational science. His expertise in navigating complex capital markets has been pivotal in sustaining investor confidence and fueling R&D investments in a competitive industry.